The Indy Autonomous Challenge Presented by Bridgestone Returns to Goodwood Festival of Speed in July 2024
11.6.2024 17:00:00 EEST | Business Wire | Press release
Returning to showcase the World’s Fastest Autonomous Racecar, the Indy Autonomous Challenge (IAC), presented by Bridgestone, will take on the hillclimb at the Goodwood Festival of Speed presented by Mastercard from July 11th to July 14th, 2024. This year, the IAC’s AV-24 fully autonomous racecar will be piloted by software from the PoliMOVE-MSU team, with support from the UNIMORE Racing team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611138772/en/
The world's fastest autonomous racecar with an AI pilot coded by students from PoliMOVE-MSU team races on Goodwood Hill. Credit Indy Autonomous Challenge. (Photo: Business Wire)
The IAC has developed the AV-24, a fully autonomous racecar utilizing a Dallara chassis used in the Indy NXT series, and outfitted with a state-of-the-art robotics platform developed with leading autonomous hardware and software providers. To date, the IAC has organized autonomous racing competitions gathering 10 teams comprised of 18 universities at prestigious venues such as the Indianapolis Motor Speedway, Las Vegas Motor Speedway, Texas Motor Speedway, and Monza F1 Circuit—affectionately known as the Temple of Speed. The 2024 Festival of Speed marks the Indy Autonomous Challenge’s competitive debut in the UK, promising to test the technology in new and challenging ways.
Since its inception in 2021, the Indy Autonomous Challenge and its university teams have set several world records for high-speed ground-based autonomy:
- Autonomous land speed record of 192.2 mph
- Highest on-track speed of 180 mph
- Fastest head-to-head overtake on-track at 177 mph
- Most miles of autonomous racing accumulated: 9,000 miles.
Last year the Indy Autonomous Challenge was introduced to Goodwood in 2023 as part of Future Lab presented by Randox, illustrating the IAC’s significant role in advancing automotive driving technology through global events. Additionally, the Technical University of Munich used their autonomous racecar to conduct a low-speed scan of the Goodwood hill, crafting a digital twin of the course that will help enable this year’s fully autonomous hillclimb.
Paul Mitchell, Chairman and President of the Indy Autonomous Challenge, expressed enthusiasm about the upcoming event, stating, “We are eager to undertake the unique challenges presented by the Goodwood Hillclimb. Unlike the familiar ovals and F1 road courses, Goodwood’s Hillclimb will challenge the precision of sensor perception, GPS localization, vehicle dynamics, and path planning in new ways, providing a historical backdrop to showcase the future of high-speed autonomous mobility and the innovative university teams behind it.”
The event, part of Goodwood’s FOS TECH program, will highlight the latest in automotive technology and alternative fuels, integrating the Future Lab and STEM programs targeted at young people eager to participate in future robotics. IAC university teams’ capabilities will be showcased as they attempt an autonomous world record on the Goodwood hill. Autonomous racing will not only entertain but also offer insights and learnings towards the future of mobility, demonstrating how AI drivers will revolutionize vehicle safety and efficiency on public roads and within supply chains.
The Duke of Richmond, founder of the Festival of Speed, commented on the festival’s role in showcasing technological innovation: “This year, our new FOS TECH ethos will bring together our future technology and mobility content. Whether exploring Future Lab presented by Randox, Electric Avenue, or enjoying content on the Hill, visitors to the Festival of Speed can experience the work of groundbreaking innovators and their vision for tomorrow’s world.”
Sara Correa, Chief Marketing Officer for Bridgestone in the Americas, Europe, Middle East and Africa (EMEA) added, “What really matters is working together to collaboratively develop and advance the future of mobility. Bridgestone is proud to partner with the IAC and its young engineers to test and improve autonomous technologies through opportunities like the Goodwood Hillclimb. Motorsports are the ultimate challenge, and the learnings we gather here can be applied to the sustainable solutions we develop for society and our customers.”
Participating teams: PoliMOVE-MSU - Comprised of members from Politecnico di Milano (Italy), Michigan State University (Michigan), with the support of UNIMORE Racing - University of Modena and Reggio Emilia (Italy)
The IAC’s appearance at Goodwood Festival of Speed will be the first time that an exhibitor has graduated from Future Lab to the Hillclimb. This year’s event will also feature engaging educational sessions, where attendees can explore future technologies such as autonomous vehicles, drones, robots, augmented and virtual reality, generative AI, sensor fusion, and the Internet of Things. These topics will be the focus of a Q&A session in collaboration with Durham University's solar-powered electric car team, which has also worked with Bridgestone to advance sustainable mobility.
Earlier in June, the IAC conducted a series of training sessions on the Goodwood Hillclimb, performing fully autonomous runs of the hill, reaching speeds greater than 177 kph (110mph). Video and photo footage of the training sessions and racecar livery renders dedicated to media use can be found here.
About the IAC: The Indy Autonomous Challenge (IAC) is a non-profit corporation based in Indianapolis, Indiana (USA) that organizes racing competitions among 10 university-affiliated teams representing 18 universities from around the world. Teams program AI drivers to pilot fully autonomous racecars and compete in a series of history-making events at iconic tracks. Based in Indiana, the IAC is working to establish a hub for performance automation in the state and is harnessing the power of innovative competitions to attract the best and the brightest minds from around the globe to further state-of-the-art technology in the safety and performance of autonomous vehicles. The IAC started as a $1 million prize competition with 31 university teams signing up to compete more than three years ago, representing top engineering and technology programs from 15 U.S. states and 11 countries. Follow the IAC @IndyAChallenge on LinkedIn, Twitter, Instagram, Facebook, and YouTube.
About Bridgestone: Bridgestone is a global leader in tires and rubber building on its expertise to provide solutions for safe and sustainable mobility. Headquartered in Tokyo, the company employs approximately 130,000 people globally and conducts business in more than 150 countries and territories worldwide. Bridgestone offers a diverse product portfolio of premium tires and advanced solutions backed by innovative technologies, improving the way people around the world move, live, work and play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611138772/en/
Contacts
Marc Ferlet
marc.ferlet@indyautonomouschallenge.com
USA: +1 317 662 5070
FR: +33 6 79 16 96 26
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom